Immix Biopharma

Immix Biopharma is a clinical-stage biopharma developing personalized therapies for oncology and immunology. Lead asset NXC-201 is a BCMA-targeting CAR-T asset, being evaluated for amyloid light chain amyloidosis and multiple myeloma, with plans to expand to autoimmune indications.

Equities

Equities by Sector

Sectors

Thematics

Latest

Banco Angolano de Investimentos S.A. – Presença crescente no comércio retalhista

Semiconductors: Materials in wafer markets

ConsumerWatch – Against all odds

Audiovisual

Latest

OSE Immunotherapeutics – equity proposition

Take on Trusts – August 2025

Cereno Scientific – executive interview

About Edison

About Edison

Careers

Immix Biopharma (NASDAQ: IMMX)

Latest Insights

Immix Biopharma — Fleshing out the CAR-T strategy

Immix Biopharma (NASDAQ: IMMX) – Potential to expand NXC-201

Immix Biopharma (NASDAQ: IMMX) – Accelerated NEXICART-2 progress

Immix Biopharma — ASCO/KOL event reaffirms NXC-201’s potential

Sector

Equity Analyst

Key Management

Immix Biopharma — All roads lead to NEXICART-2

Immix Biopharma — Reaffirmed long-term focus on outpatient CAR-T

Immix Biopharma — Marching towards US clinical trials for NXC-201

Immix Biopharma — 2023 recap with a preview of active year ahead

Immix Biopharma — Updates galore: NXC-201 ODD (EU) and raise

Immix Biopharma — Increased legroom following common-only raise

Immix Biopharma — Encouraging stream of ALA data newsflow

Immix Biopharma — KOL event: Glimmer of hope for ALA patients

Immix Biopharma — CAR-T trial moves to US with outpatient potential

Immix Biopharma — A quarter of progress for both lead assets

Immix Biopharma — A step toward delivering a practical CAR-T option

Immix Biopharma — NXC-201 gains orphan drug designation in ALA

Immix Biopharma — NXC-201 gains Orphan Drug designation in MM

Immix Biopharma — Progressing as expected on all fronts

Immix Biopharma — IMX-110 interim results in colorectal cancer

Immix Biopharma — ATM completion may extend runway into H224

Immix Biopharma — A quarter focusing on a CAR-T strategy

Immix Biopharma — CAR-T treatment continues to show promise

Immix Biopharma — Pipeline momentum continues in FY23

Immix Biopharma — Positive data from CAR-T treatment continues

Immix Biopharma — Expanding portfolio into CAR-T cell therapy

Immix Biopharma — Encouraging progress on multiple fronts

Immix Biopharma — Potential upside with expansion into CAR-T

Immix Biopharma — IMX-110 clinical expansion on the horizon

Immix Biopharma – executive interview

Immix Biopharma — Fresh faces with a unique tissue-targeting therapy